Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Nov 15;22(12):1344-52.

Management of myelodysplastic syndromes: 2008 update

Bart L Scott  1 , Eli Estey
Affiliations
Review

Management of myelodysplastic syndromes: 2008 update

Bart L Scott et al. Oncology (Williston Park). .

Abstract

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic disorders characterized by low blood counts and a tendency to progress to acute myeloid leukemia. Treatment options have increased over the past 10 years, and many new agents are currently being investigated. In this article, we review the diagnosis of MDS, prognostic systems, and treatment options, including supportive care, erythropoiesis-stimulating agents, antithymocyte globulin, lenalidomide, azacitidine, decitabine, intensive chemotherapy, and hematopoietic cell transplantation.

PubMed Disclaimer

Figures

Figure 1
Figure 1. IPSS Prognosis
(A) Survival by IPSS category. (B) Risk of AML evolution by IPSS category. AML = acute myeloid leukemia; Int = intermediate; IPSS = International Prognostic Scoring System. This research was originally published in Blood. Adapted, with permission, from Greenberg P et al.[6] Copyright © 1997 by the American Society of Hematology.
Figure 2
Figure 2. WPSS Prognosis
(A) Survival and (B) risk of AML by WPSS in the German cohort by time-dependent analysis. AML = acute myeloid leukemia; WHO = World Health Organization; WPSS = WHO Classification-Based Prognostic Scoring System. Adapted, with permission, from Malcovati L et al.[8] Copyright © 2007 by the American Society of Clinical Oncology. All rights reserved.
Figure 3
Figure 3. Impact of Decitabine on Survival
Survival probability in a matched retrospective cohort analysis comparing decitabine to intensive chemotherapy. Adapted, with permission, from Kantarjian HM et al.[35]
Figure 4
Figure 4. Impact of IPSS Score on Outcome
Relapse-free survival by IPSS category following hematopoietic stem cell transplantation. IPSS = International Prognostic Scoring System. This research was originally published in Blood. Adapted, with permission, from Deeg HJ et al.[36] Copyright © 2002 by the American Society of Hematology.
Figure 5
Figure 5. Life Expectancy and Transplantation Delay
Gain vs loss in life expectancy with delay in hematopoietic stem cell transplantation by IPSS category. Int = intermediate; IPSS = International Prognostic Scoring System. This research was originally published in Blood. Adapted, with permission, from Cutler CS et al.[38] Copyright © 2004 by the American Society of Hematology.
See this image and copyright information in PMC

Comment on

References

    1. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112:45–52. - PubMed
    1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302. - PubMed
    1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199. - PubMed
    1. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol. 2005;23:7594–7603. - PubMed
    1. Howe RB, Porwit-MacDonald A, Wanat R, et al. The WHO classification of MDS does make a difference. Blood. 2004;103:3265–3270. - PubMed

MeSH terms